Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effects of Ziprasidone 320 mg on Glucose and Plasma Lipids in Patients With Diabetes Type II and Schizophrenia or Schizoaffective Disorder

NCT00395031 is registered in ClinicalTrials.gov with Manhattan Psychiatric Center as lead sponsor.

NCT NCT00395031
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00395031 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effects of Ziprasidone 320 mg on Glucose and Plasma Lipids in Patients With Diabetes Type II and Schizophrenia or Schizoaffective Disorder
Lead sponsor
Manhattan Psychiatric Center
Phase
Phase 2/3
Overall status
Completed
Start date
September 30, 2003
Completion date
January 31, 2010
Enrollment
57 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizoaffective disorder, schizophrenia